← Back to Search

Other

D-0502 for Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by InventisBio Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Limited number of prior chemotherapy, endocrine therapy, and targeted therapy for advanced or metastatic disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights

Study Summary

This trial is testing a new drug, D-0502, to see if it is safe and if it works against breast cancer.

Eligible Conditions
  • Breast Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have only received a small number of treatments in the past for your advanced or metastatic disease, including chemotherapy, hormone therapy, or targeted therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria
Secondary outcome measures
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
Maximum observed serum concentration (Cmax)
Objective response rate (ORR)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: D-0502 in combination with palbociclibExperimental Treatment2 Interventions
D-0502 in combination with palbociclib
Group II: D-0502Experimental Treatment1 Intervention
D-0502
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
D-0502
2018
Completed Phase 1
~240
palbociclib
2020
Completed Phase 2
~1230

Find a Location

Who is running the clinical trial?

InventisBio Inc.Lead Sponsor
7 Previous Clinical Trials
695 Total Patients Enrolled
1 Trials studying Breast Cancer
14 Patients Enrolled for Breast Cancer
InventisBio Co., LtdLead Sponsor
19 Previous Clinical Trials
1,755 Total Patients Enrolled
1 Trials studying Breast Cancer
14 Patients Enrolled for Breast Cancer

Media Library

D-0502 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03471663 — Phase 1
Breast Cancer Research Study Groups: D-0502, D-0502 in combination with palbociclib
Breast Cancer Clinical Trial 2023: D-0502 Highlights & Side Effects. Trial Name: NCT03471663 — Phase 1
D-0502 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03471663 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers have enrolled for this investigation?

"All current recruitment for this trial has been completed. This medical experiment was first publicized on March 18th, 2018 and recently updated on May 5th 2022. For those seeking alternative studies to participate in, there are presently 2600 trials aimed at recruiting breast cancer patients and 133 trails that need volunteers for D-0502 research."

Answered by AI

How many locations are actively participating in the trial's execution?

"Currently, this research is enrolling participants from ten distinct sites. These include Aurora, Eugene and Greenville as well as other nearby regions which may be more convenient for prospective study-members to visit."

Answered by AI

What maladies is D-0502 typically utilized to ameliorate?

"D-0502 is a pharmaceutical often prescribed to address breast malignancies, postmenopausal symptoms, and advance directives."

Answered by AI

Are there any other studies utilizing D-0502 as a form of treatment?

"At present, 133 trials utilizing D-0502 are ongoing. Out of those studies, 16 have progressed to Phase 3 clinicals. While most investigations occur in Burgas, New jersey; there is a total of 6577 sites around the world conducting research for this medication."

Answered by AI

Has D-0502 obtained regulatory approval from the Food and Drug Administration?

"D-0502 has only been tested in a few clinical trials, so its safety rating is 1. This indicates that there is limited evidence backing up the efficacy of this drug."

Answered by AI

Are there any vacancies available for individuals to partake in this clinical investigation?

"At present, this medical trial is not enrolling new patients. Initially posted on March 18th 2018 and last updated on May 5th 2022, it is currently inactive. Those looking for clinical trials can find 2600 studies recruiting breast cancer patients, as well as 133 related to D-0502 which are actively admitting participants."

Answered by AI
~29 spots leftby Mar 2025